D.A. Davidson & Co. Biomarin Pharmaceutical Inc Transaction History

D.A. Davidson & Co.

$15.1 Billion
Q3 2025

A detailed history of D.A. Davidson & Co. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, D.A. Davidson & Co. holds 10,874 shares of BMRN stock, worth $595,134. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,874

Previous 7,119 52.75%

Holding current value

$595,134

Previous $391,000 50.38%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 22, 2025	BUY	$52.62 - $61.93 $197,588 - $232,547	3,755 Added 52.75%	10,874 $588,000
Q2 2025 Jul 30, 2025	BUY	$54.08 - $68.32 $17,900 - $22,613	331 Added 4.88%	7,119 $391,000
Q1 2025 Apr 28, 2025	SELL	$61.25 - $72.83 $45,692 - $54,331	-746 Reduced 9.9%	6,788 $479,000
Q4 2024 Jan 31, 2025	BUY	$61.93 - $70.49 $466,580 - $531,071	7,534 New	7,534 $495,000
Q3 2020 Nov 02, 2020	SELL	$71.87 - $131.03 $379,761 - $692,362	-5,284 Closed	0 $0

Q2 2020 Aug 10, 2020	SELL	$79.55 - $124.22 $6,761 - $10,558	-85 Reduced 1.58%	5,284 $652,000
Q1 2020 May 05, 2020	BUY	$71.37 - $96.85 $16,629 - $22,566	233 Added 4.54%	5,369 $454,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $127,061 - $170,753	1,977 Added 62.58%	5,136 $434,000
Q3 2019 Nov 05, 2019	BUY	$67.4 - $85.11 $212,916 - $268,862	3,159 New	3,159 $213,000
Q3 2017 Nov 08, 2017	SELL	$80.6 - $94.95 $20,150 - $23,737	-250 Closed	0 $0
Q2 2017 Aug 11, 2017	BUY	N/A	250	250 $0

Others Institutions Holding BMRN

# of Institutions

667

Shares Held

182M

Call Options Held

1.48M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account